Fidelity Investments’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Fidelity Investments’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-23,107	Closed	-$68K	–	4417
2018 Q3	$68K	Sell	23,107 -655,870	-97%	-$2.32M	﹤0.01%	2773
2018 Q2	$2.5M	Hold	678,977	–	–	﹤0.01%	2300
2018 Q1	$2.38M	Hold	678,977	–	–	﹤0.01%	2338
2017 Q4	$2.12M	Hold	678,977	–	–	﹤0.01%	2347
2017 Q3	$4.77M	Hold	678,977	–	–	﹤0.01%	2173
2017 Q2	$6.27M	Buy	678,977 +97,500	+17%	+$939K	﹤0.01%	2106
2017 Q1	$6.25M	Sell	581,477 -31,800	-5%	-$325K	﹤0.01%	2120
2016 Q4	$5.16M	Buy	+613,277	New	+$5.43M	﹤0.01%	2171

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's NVLN Position: Q4 2018 in Review

Fidelity Investments sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 23,107 shares — an estimated $68K sold.

Fidelity Investments first reported a position in NVLN in Q4 2016 and held it in 8 quarters. The position peaked at $6.27M in Q2 2017. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

Fidelity Investments reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
Fidelity Investments sold 23,107 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $68K.
Fidelity Investments first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 8 quarters.
Fidelity Investments's Novelion Therapeutics Inc. Common Shares position peaked at $6.27M in Q2 2017.
36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Fidelity Investments's 13F filing for Q4 2018, filed 13 Feb 2019.